Evofosfamide

DRUG4 trials

Conditions

Castration Resistant Prostate CancerMelanomaMetastatic Head and Neck Squamous Cell CarcinomaMetastatic Pancreatic CancerMetastatic Prostate CancerPancreatic CancerProstate CancerSolid Tumor

Phase 1

A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer

CompletedNCT01833546

Merck KGaA, Darmstadt, GermanyPancreatic Cancer, Solid Tumor

Start: 2013-04-18End: 2016-01-25Updated: 2018-10-15

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

NCT03098160

Threshold PharmaceuticalsMelanoma, Pancreatic Cancer, Prostate Cancer +1

Start: 2017-05-10End: 2019-04-30Target: 69Updated: 2017-10-30

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

RecruitingNCT06782555

ImmunoGenesisMetastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer, Metastatic Prostate Cancer

Start: 2025-01-08End: 2028-01-31Target: 71Updated: 2025-01-21

Phase 2

Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer

Not yet recruitingNCT06836726

University Health Network, TorontoCastration Resistant Prostate Cancer

Start: 2026-05-27End: 2030-05-27Target: 35Updated: 2026-01-28

Regular and Young Investigator Award Abstracts2022-11-011 citations

Abstract 4231: Hypoxia reduction in tandem with anti-angiogenic therapy remodels the pancreatic tumor microenvironment

Cancer Research2022-06-15

A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies

Clinical Cancer Research2021-03-2658 citations

Abstract IA11: Reversal of immunotherapy resistance through hypoxia reduction

Clinical Cancer Research2020-06-152 citations

Evofosfamide

Sponsors

Conditions

Phase 1

Phase 2

Related Papers